Valuation: AC Immune SA

Market Cap 186M 228M 200M 170M 321M 22B 326M 2.21B 864M 10.75B 855M 837M 37.16B P/E 2026 *
-6.32x
P/E 2027 * 10.2x
Enterprise Value 141M 173M 151M 129M 243M 16.69B 247M 1.68B 655M 8.16B 649M 635M 28.19B EV / Sales 2026 *
3.88x
EV / Sales 2027 * 2.31x
Free-Float
56.09%
Yield 2026 *
-
Yield 2027 * -
1 day-1.30%
1 week-5.81%
Current month-4.62%
1 month-5.42%
3 months-20.91%
6 months-33.24%
Current year-27.71%
1 week 2.12
Extreme 2.12
2.35
1 month 2.12
Extreme 2.12
2.66
Current year 2.1
Extreme 2.095
3.9
1 year 2.03
Extreme 2.03
4
3 years 1.43
Extreme 1.4299
5.14
5 years 1.43
Extreme 1.4299
12.61
10 years 1.43
Extreme 1.4299
19.97
Manager TitleAgeSince
Chief Executive Officer 64 2026-06-10
Director of Finance/CFO 37 2021-12-31
Chief Tech/Sci/R&D Officer 45 2012-12-31
Director TitleAgeSince
Director/Board Member 70 2018-12-31
Director/Board Member 72 2020-11-19
Director/Board Member 65 2021-10-28
Date Insider Type Main position Quantity % Market Cap.
6/11/26 Free

Director

55,457 0.0545%
6/11/26 Free

Chief Executive Officer

110,914 0.1090%
6/11/26 Free

Director

55,457 0.0545%
Change 5-day change 1-year change 3-year change Capi.($)
-1.30%-5.81%+9.13%-25.57% 228M
-3.56%-0.75%+19.37%-11.36% 68.69B
-0.25%+4.65%+40.39%+196.63% 52.97B
-1.65%+37.20%+37.20%+37.20% 43.61B
-2.83%-4.08%-53.81%-55.84% 40.75B
-2.67%+3.02%+61.18%-28.55% 29.99B
-2.67%-13.89%+87.50%-54.07% 23.67B
-1.36%+0.79%+71.85%+80.50% 23.45B
+0.11%+2.44%+4.06%+181.25% 20.46B
-0.39%+2.03%+72.19%+122.26% 16.66B
Average -1.66%+0.15%+34.91%+44.25% 32.05B
Weighted average by Cap. -1.95%+1.22%+30.51%+45.16%

Financials

2026 *2027 *
Net sales 36.27M 44.51M 39.01M 33.28M 62.69M 4.3B 63.68M 432M 169M 2.1B 167M 164M 7.26B 87.76M 108M 94.4M 80.53M 152M 10.4B 154M 1.05B 409M 5.08B 404M 396M 17.57B
Net income -30.36M -37.25M -32.65M -27.86M -52.47M -3.6B -53.3M -362M -141M -1.76B -140M -137M -6.08B 17.54M 21.52M 18.87M 16.1M 30.32M 2.08B 30.8M 209M 81.65M 1.02B 80.82M 79.09M 3.51B
Net Debt -44.8M -54.98M -48.19M -41.11M -77.44M -5.31B -78.66M -534M -209M -2.6B -206M -202M -8.97B 17.1M 20.99M 18.39M 15.69M 29.56M 2.03B 30.02M 204M 79.61M 991M 78.8M 77.11M 3.42B
Logo AC Immune SA
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Employees
106
Date Price Change Volume
26-07-22 US$2.270 -1.30% 245,506
26-07-21 US$2.300 +2.22% 94,875
26-07-20 US$2.250 +2.27% 206,955
26-07-17 US$2.200 +0.92% 356,184
26-07-16 US$2.180 -7.63% 238,883
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.846CHF
Average target price
6.956CHF
Spread / Average Target
+276.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACIU Stock